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Achievement of a busulfan area-under-the-concentration versus time curve (AUC) of 900 to 1500 mM$min is
associated with improved hematopoietic stem cell transplant (HSCT) outcomes. Multiple pediatric busulfan
dosing guidelines aim to achieve this target. The authors’ objective was to describe the AUCs achieved after
simulated dosing using available pediatric i.v. busulfan dosing guidelines. The health records of children who
received i.v. busulfan for HSCT conditioning at The Hospital for Sick Children were reviewed. Busulfan AUCs
were calculated for each patient based on plasma busulfan concentrations using either a 1-compartment
model or a validated limited-sampling strategy. Published pediatric busulfan dosing guidelines were identi-
ﬁed. Initial busulfan doses were determined for all patients using each dosing guideline and total body weight
(TBW). For overweight patients (TBW-to-ideal body weight [IBW]  1.25), initial busulfan doses were also
determined using IBW and adjusted IBW (IBWadj). The resulting AUCs were simulated. The proportion of
subjects (TBW/IBW < 1.25, TBW/IBW  1.25, and infants) with an AUC within target (900 to 1500 mM$min)
after dosing simulation with each guideline was compared. One hundred eleven children (mean age, 6.2 years
[SD, 5.2]) who received i.v. busulfan were included. When dosing with each of the 12 i.v. busulfan dosing
guidelines identiﬁed was simulated using TBW in 97 non-overweight patients, the proportion of patients with
an AUC within the target range varied from 51% to 74% and from 45% to 64% in infants. Use of IBW or IBWadj to
calculate initial busulfan doses in overweight children improved the performance of most guidelines. Current
busulfan dosing guidelines vary in their ability to achieve AUCs within the target range. For children who are
not overweight, we recommend 1 of 3 high-performing guidelines that allow individualization of the target
busulfan AUC. Use of either IBW or IBWadj in overweight children improves the performance of most guide-
lines. Regardless of the guideline used, therapeutic drug monitoring is essential to verify achievement of the
target AUC.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Busulfan is a cytotoxic alkylating agent that is widely used
in pediatric hematopoietic stem cell transplantation (HSCT)
conditioning regimens. The area-under-the concentration-
versus-time curve (AUC) or its counterpart, the steady-state
concentration (Css), best describes the relationship
between the pharmacokinetic and pharmacodynamicdgments on page 1478.
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ty for Blood and Marrow Transplantation.properties of busulfan [1]. An increase in the probability of
toxicity, such as hepatic veno-occlusive disease at higher
AUCs coupled with concerns of engraftment failure at lower
AUCs, has resulted in the general acceptance of a target AUC
range of 900 to 1500 mM$min for every-6-hour dosing and
3600 to 6000 mM$min for every-24-hour dosing [2,3].
A number of pediatric dosing guidelines have been
developed to assist in determining the initial dose of i.v.
busulfan. However, each dosing guideline may differ in the
proportion of patients who achieve the target AUC based on
the doses they suggest. They may also have a tendency to
produce AUCs in the upper or lower end of the target range. A
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dosing guidelines is lacking. The primary objective of this
study was to describe the performance of the published
pediatric initial i.v. busulfan dosing guidelines with respect
to the busulfan AUC values they achieve and their likelihood
to achieve an AUC within the therapeutic target. Because it is
unclear that total body weight (TBW) is appropriate for dose
calculation in overweight patients, we also aimed to describe
the performance of different weight descriptors to calculate
the initial busulfan dose for overweight children.
METHODS
This study was developed as a Quality Improvement project and
approved by the Quality and Risk Management Department at The Hospital
for Sick Children.
Retrospective Chart Review
A retrospective, single-center chart review of 111 children who under-
went HSCT and received i.v. busulfan from April 2003 to January 2006 and
were part of a pre-existing data set [4] or from December 2010 to December
2013 at The Hospital for Sick Children in Toronto was undertaken. Children
were identiﬁed through pharmacy records, and the following data were
extracted from their health records: demographic information (age, gender,
weight, and height on day 1 of busulfan administration), HSCT data (indi-
cation for HSCT, conditioning regimen, and seizure prophylaxis), and
busulfan pharmacokinetic data (dose, time of administration, infusion
duration, sampling times, and corresponding plasma concentrations).
Plasma busulfan concentrations were assayed by gas chromatography with
electron capture detection by The Hospital for Sick Children laboratory.
Busulfan Dosing Regimen Identiﬁcation
With the assistance of a library scientist, electronic searches of OVID
Medline (1980 to March 2015), EMBASE (1980 to March 2015), and PubMed
(to March 22, 2015) were conducted. The systematic literature search was
limited to English studies in a pediatric setting using i.v. busulfan for HSCT
conditioning. The search strategy is presented in Table 1.
Busulfan Dosing and AUC Simulation
For clinical purposes, each patient’s busulfan AUCwas calculated using a
1-compartment model (PhoenixWinNonLin 6.3; Pharsight, St. Louis, MO) or
a validated limited-sampling strategy [5]. Simulated busulfan doses were
calculated using each of the identiﬁed i.v. busulfan pediatric dosing guide-
lines for each patient identiﬁed in the chart review.
Doses were estimated assuming an every-6-hour dosing schedule.
Therefore, doses proposed by every-24-hour dosing guidelines were divided
by 4. When dosing guidelines dosed busulfan according to body weight tiers
(eg, 10 to 20 kg), the patient’s body weight was rounded down to the lower
weight category but the busulfan dose was calculated using their TBW for
simulation. For example, the dosing guideline of Bartelink et al. [6] advises
that patientswhoweigh13 or 15 kg receive busulfan 1.3 or 1.275mg/kg/dose,Table 1
Literature Search Strategy
Study No. Search Strategy
1 Busulfan/ad [Administration & Dosage]
2 Busulfan/
3 Drug Dosage Calculations/
4 2 and 3
5 1 or 4
6 Limit 5 to “all child (0 to 18 years)”
7 Limit 6 to English language
8 Exp Hematopoietic Stem Cells/
9 Cord blood stem cell transplantation/or hematopoietic
stem cell transplantation
10 (“hematopoietic stem cell? transplant*” or “stem cell?
transplant* hematopoietic” or “transplant* hematopoietic
stem cell?” or “haematopoietic stem cell? transplant*” or
“stem cell? Transplant* haematopoietic” or “transplant*
haematopoetic stem cell?” or “placental blood stem cell?
transplant*” or “cord blood stem cell? transplant*” or
“haematopoietic stem cell? therap*” or “hematopoietic
stem cell? therap*”).tw.
12 8 or 9 or 10
13 7 and 12respectively. For the purposes of this study, dosing for a 14-kg patient was
simulated according to the guideline for a 13-kg patient (1.3mg/kg/dose), but
the ﬁnal dose (18.2 mg/dose) was calculated with the patient’s TBW (14 kg).
In addition, a target AUCof 1250 mM$min (equivalent to a Css of 850 mg/L)was
used in dosing guidelines that required a target AUC for dose calculationwith
the exceptionof the dosing guideline of Long-Boyle et al. [7],where anAUC of
1242 mM$min was targeted because of limitations of the accompanying
electronic dose calculator.
Finally, busulfan dosing guidelines were assessed according to the
population in whom they were developed. For example, if the busulfan
dosing guideline was limited to patients  12 kg, only patients who met this
criterion were included in the evaluation of the performance of that
guideline. The predicted busulfan AUC achieved by simulated administra-
tion of the proposed dose was determined assuming a linear relationship
between dose and AUC as follows: AUCsimulated ¼ (AUCobserved/Doseinitial) 
Doseproposed, where Doseinitial (mg) is the ﬁrst busulfan dose given to the
patient, AUCobserved (mM$min) is the busulfan AUC calculated after Doseinitial,
Doseproposed is the dose proposed by a dosing guideline, and AUCsimulated is
the predicted AUC achieved by simulated administration of proposed dose.
The results of busulfan dose simulation in infants < 1 year of age were also
assessed separately.
Ideal body weight (IBW) was calculated for all patients using the
following equation: IBW (kg)¼ 2.396e(.01863  height[cm]) [8]. For the purposes
of this study, patients with a TBW/IBW ratio  1.25 were deemed to be
overweight [9]. The simulated dose proposed by each busulfan dosing
guideline identiﬁed was calculated based on TBW, IBW, and adjusted IBW
(IBWadj) for overweight patients [9,10]. IBWadj was calculated based on each
patient’s TBW/IBW ratio. For patients with a TBW/IBW ratio of 1.25 to 1.75,
IBWadj was calculated using the following equation: IBWadj ¼ .25 (TBW 
IBW)þ IBW. For patients with a TBW/IBW ratio> 1.75, IBWadj was calculated
using the following equation: IBWadj ¼ .4 (TBW  IBW) þ IBW.
Statistical Analysis
Data were analyzed using descriptive statistics. Between-guideline
comparisons of the proportion of patients achieving an AUC within the
target range was performed using Pearson chi-square test (SAS Enterprise
Guide 6.100; SAS Institute Inc., Cary, NC). Differences identiﬁed in this
analysis were further explored using analysis of proportions [11].
RESULTS
Retrospective Chart Review
Demographic data regarding the 111 patients included in
this chart review are presented in Table 2. Busulfanwas given
as the ﬁrst conditioning agent and, with the exception of
ﬂudarabine regimens, was the only conditioning agent on
each day of administration. In patients receiving condition-
ing with busulfan plus ﬂudarabine, ﬂudarabine was started
on the second day of busulfan administration. The mean AUC
calculated after the ﬁrst busulfan dose was 1200 mM$min
(95% conﬁdence interval, 1145 to 1255). The target AUC value
was achieved in 66% of patients.
Busulfan Dosing Regimen Identiﬁcation
Eleven publications describing 12 busulfan dosing
guidelines were identiﬁed (Table 3) [6,7,12-20]. One dosing
guideline [19] was supplemented by an online dosage
calculation tool (see http://holford.fmhs.auckland.ac.nz/
docs/busulfan-integrated-pk.pdf) [21]. Another was supple-
mented by an Excel-based dose calculator tool (Dr. J. R. Long-
Boyle, personal communication, March 16, 2015). Three
dosing guidelines appear to have been developed using the
same data [18,20,22]. The actual dosing guidelines are
summarized in Appendix 1. Six guidelines [6,13-15,17,18]
used body weight to determine the initial dose of busulfan;
2 guidelines [16,20] used age, 2 [7,12] used a combination of
body weight and age, 1 guideline [17] used body surface area
(BSA), whereas another used an equation based on busulfan
clearance scaled to normal fat mass based on sex, age, and
height [19]. Six dosing guidelines included the target AUC or
Css as a variable [7,12,14,17,19]. Three dosing guidelines had
weight restrictions: Buffery et al. [13] excluded patients with
Table 2
Information Regarding the 111 Children Included in Retrospective Evalua-
tion of Busulfan AUC
Characteristic Value
Demographic information
Mean age, yr (range) 6.2 (.3-17.4)
Male sex (%) 63 (57)
Mean TBW, kg (range) 26.4 (4.8-108.7)
Mean BSA, m2 (range) .87 (.27-2.27)
TBW/IBW  1.25 (%) 14 (13)
Indication for HSCT (%)
Malignant 71 (64)
Acute myelogenous leukemia 37 (33)
Neuroblastoma 11 (10)
Myelodysplastic syndrome 8 (7)
Juvenile chronic myelogenous leukemia 5 (5)
Hemophagocytic lymphohistiocytosis 5 (5)
Medulloblastoma 3 (3)
Other* 3 (3)
Nonmalignant 39 (35)
Severe combined immunodeﬁciency 12 (11)
Hurler syndrome 6 (5)
Thalassemia 5 (5)
Wiskott-Aldrich syndrome 4 (4)
Adrenoleukodystrophy 3 (3)
Osteopetrosis 3 (3)
Othery 6 (5)
Conditioning regimen (%)
Busulfan þ
Cyclophosphamide 45 (41)
Cyclophosphamide þ thymoglobulin 31 (28)
Melphalan 12 (11)
Fludarabine þ thymoglobulin 8 (7)
Cyclophosphamide þ etoposide 5 (5)
Thiotepa 3 (3)
Otherz 7 (6)
Seizure prophylaxis administered (%)
Phenytoin 109 (98)
Lorazepam 2 (2)
* Other: acute lymphoblastic leukemia, retinoblastoma.
y Other: congenital amegakaryocytic thrombocytopenia, IPEX syndrome,
Niemann-Pick disease, chronic granulomatous disease, autoimmune lym-
phoproliferative syndrome, STAT1 deﬁciency.
z Other: busulfan plus: ﬂudarabine; cyclophosphamide þ alemtuzumab;
cyclophosphamide þ melphalan þ etoposide.
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> 12 kg, and the supplementary dose calculator tool for
the Long-Boyle dosing guideline excluded patients < 12 kg
and those > 17 years of age (Dr. J.R. Long-Boyle, personal
communication, March 16, 2015).
AUC Simulation using TBW in Non-Overweight Patients
Because of dosing guideline limitations, 64 patients with
a TBW > 12 kg were excluded from the Savic et al. [12] dose
simulations, 23 patients with a TBW < 10 kg were excluded
from the Buffery et al. [13] dose simulations, and 34 patients
with a TBW< 12 kg (33 patients) or were older than 17 years
(1 patient) were excluded from the Long-Boyle et al. [7] dose
simulations.
The simulated AUC values produced by each dosing
guideline using TBW for non-overweight patients are pre-
sented in Table 4 and Figure 1. The mean simulated AUC
values achieved using all but 1 guideline was within the
target range. Simulation with the guideline developed by
Savic et al. [12] achieved a mean simulated AUC value (1505
mM$min) that was just above the upper limit of the target
range. The coefﬁcient of variation in themean simulated AUC
values achieved using TBW ranged from 20.3% to 30.5%. The
proportion of children who achieved a simulated AUC value
within the target range after simulated dosing differedamong the guidelines (P ¼ .0011). The lower and upper
decision limits for the proportion of patients achieving an
AUC value within the target range after dose simulationwere
58.4% and 66.2%, respectively. The dosing guidelines devel-
oped by Bartelink et al. [6], Buffery et al. [13], Long-Boyle
et al. [7], McCune et al. [19], Nguyen et al. [22], and Paci
et al. [14] exceeded the upper decision limit and thus resul-
ted in a signiﬁcantly higher proportion of patients achieving
an AUC value within the target range than average (Table 4).
Conversely, the proportion of AUC values within the target
range achieved after simulated dosing with the guidelines
developed by Ansari et al. [16], Booth et al. [18], Savic et al.
[12], Trame et al. (allometric body weight or BSA) [17], or
Wall et al. [20] fell below the lower decision limit. Simulated
dosing with these guidelines resulted in a signiﬁcantly lower
proportion of patients achieving an AUC value within the
target range than average.AUC Simulation using TBW in Infants
Because of dosing guideline limitations, the guidelines
developed by Long-Boyle et al. [7] and Buffery et al. [13] were
not able to applied in this subanalysis. The TBWof all but 2 of
these infants was less than their IBW and the TBW/IBW ratio
was <1.25 in all patients. Consequently, busulfan dose
simulation was undertaken only with TBW. The results of i.v.
busulfan dose simulation in 22 infants < 1 year of age are
presented in Table 5. The proportions of children who ach-
ieved a simulated AUC value within the target range after
simulated dosing did not differ signiﬁcantly among the
guidelines (P ¼ .9410).AUC Simulation using TBW, IBW, and IBWadj in
Overweight Patients
Fourteen patients were deﬁned as overweight. The dosing
guideline proposed by Savic et al. [12] was not included in
the analysis of overweight patients, because none had a TBW
< 12 kg. One patient’s TBW was 20% higher than the
uppermost body weight category included in the Bartelink
et al. [6] dosing guideline. A decision was made to exclude
this patient from the dose simulation using this guideline.
Similarly, dosing using IBWor IBWadj was not explored using
the dosing guidelines developed by McCune et al. [19]
because this guideline included an adjustment for body fat
when TBW is used. This notwithstanding, only 6 of 14 over-
weight children (43%) achieved an AUC within the target
range using the initial busulfan dose calculated using this
guideline (Table 6).
The proportions of children who achieved a simulated
AUC value within the target range after simulated dosing
differed signiﬁcantly among the guidelines when TBW was
used to calculate doses (P ¼ .0376). However, no differences
were seenwhen IBWand IBWadj were used to calculate doses
(IBW: P ¼ .0717; IBWadj: P ¼ .1223). Using TBW for dose
calculation, the lower and upper decision limits for the
proportion of patients achieving an AUC value within the
target range after dose simulation were 49.0% and 57.3%,
respectively. The dosing guidelines developed by Paci et al.
[14] and Trame et al. (allometric body weight or BSA) [17]
exceeded the upper decision limit and thus resulted in a
signiﬁcantly higher proportion of patients achieving an AUC
value within the target range than average (Table 7). Simu-
lated dosing with the guidelines developed by Bartelink et al.
[6], Buffery et al. [13], Long-Boyle et al. [7], McCune et al. [19],
and Nguyen et al. [22] resulted in a signiﬁcantly lower
Table 3
Comparison of 12 i.v. Busulfan Pediatric Dosing Guidelines
Dosing Guideline
(First Author, Year
of Publication)
Target AUC
(mM$min)
PK Model Parameter for
Dosage Calculation
Number of Patients
Used in Development
Patients’ Age Range (yr) Patient Diagnoses (%) Seizure Prophylaxis (%) Overweight
Patients (%)
Ansari, 2014 1096.25 (mean) One compartment Age 75 .1-20 Malignant (64)
Nonmalignant (36)
Midazolam, lorazepam or
phenytoin
NR
Bartelink, 2012 1350 Two compartment TBW Development: 245
Evaluation: 158
Development: .1-26
Evaluation: .1-35
Development: Malignant (46.5),
other (55)
Evaluation: Malignant (24.7),
other (75.3)
Development: Clobazam,
clonazepam,
diazepam, phenytoin
Evaluation: NR
Development* (17)
Evaluation* (9)
Booth, 2007 1125 (mean) One compartment TBW 24 .25-16.7 Malignant (62.5)
Other (37.5)
Phenytoin (100) NR
Buffery, 2014 900-1400 One compartment TBW 144 (89 pediatric) .5-58 Malignant diseases: 76%
Other: 24%
NR NR
Long-Boyle, 2015 Css: 600-900 ng/mL Michaelis-Menten TBW and age Development: 90
Evaluation: 21
Development: .1-24
Evaluation: .4-13.3
NR Lorazepam or Levatiracetam NR
McCune, 2014 Css: 770 ng/mL Two compartment
with ﬁrst-order
elimination
Scaled to normal
fat mass
1610 patients;
<20 yr: 1481 patients
.1-65.8 Malignant: 75%
Nonmalignant: 25%
NR NR
Nguyen, 2004 1125 One compartment TBW Development: 24
Evaluation: 55
Development: .45-16.7
Evaluation: .3-17.2
Development: Malignant (62.5),
other (37.5)
Evaluation: Malignant (83.6),
other (16.4)
Development: Phenytoin (95.8)
Phosphenytoin (4.2)
Evaluation: Clonazepam (100)
NR
Paci, 2012 1,200 One compartment TBW 205 .03-15 Malignant (42)
Other (58)
Benzodiazepine (89)
Phenytoin (11)
NR
Savic, 2013 1098 One compartment TBW and age 149 .1-3.3 NR NR NR
Tramey, 2011 1125 and 1150 One compartment BSA and
allometric BW
Development: 94
Evaluation: 24
Development: .4-18.8
Evaluation: .1-18.9
NR Development: Clonazepam
or phenobarbitol
Evaluation: NR
NR
Wall, 2010 1125 (mean) One compartment Age 24 .5-3.8 Malignant (62.5)
Other (37.5)
Phenytoin (100) NR
NR indicates not reported; BW, body weight.
* Overweight deﬁned as body mass index >95th percentile.
y Trame proposed 2 dosing regimens: 1 based on TBW and 1 based on BSA.
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Table 4
AUC Values Achieved and Their Distributionwith Respect to the Target Range after Dosing Simulationwith 12 i.v. Busulfan Dosing Guidelines in 97 Patients with
TBW/IBW Ratio < 1.25 When Dosed Using TBW
Dosing Guideline (Author, Year of Publication) Simulated AUC Values Distribution of Simulated AUC Values (% of
Patients)
Mean AUC (SD)
mM$min
95% Conﬁdence
Interval
CV (%) 900-1500
mM$min
<900
mM$min
>1500
mM$min
Dosing guidelines that allow ﬂexible AUC targets
Long-Boyle*, 2015 1374 (279.1) 1305-1443 20.3 67 3 30
McCune, 2014; ﬁrst dose 1332 (302.0) 1276-1388 22.7 74 3 23
Paci, 2012 1256 (317.4) 1193-1319 25.3 72 8 20
Savicy, 2013 1505 (381.2) 1375-1635 25.3 58 3 39
Trame, allometric BW method, 2011 1063 (306.5) 1002-1124 28.8 55 34 11
Trame, BSA method, 2011 1050 (303.8) 989-1110 28.9 54 36 10
Dosing guidelines that do not allow ﬂexible AUC targets
Ansari, 2014 1024 (247.1) 974-1073 24.1 56 38 6
Bartelink, 2012 1409 (310.1) 1347-1471 22.0 67 0 33
Booth, 2007 1088 (332.4) 1022-1154 30.5 51 36 13
Bufferyz, 2014 1169 (281.9) 1105-1233 24.1 70 18 12
Nguyen, 2004 1234 (278.8) 1179-1290 22.6 70 13 16
Wall, 2010 1081 (280.5) 1025-1137 26.0 56 33 11
SD indicates standard deviation; CV, coefﬁcient of variation.
* Sixty-three patients included in simulation; 33 patients excluded due to TBW  12 kg; 1 patient excluded due to age > 17 years.
y Thirty-three patients included in simulation; 64 patients excluded due to TBW > 12 kg.
z Seventy-four patients included in simulation; 23 patients excluded due to TBW < 10 kg.
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target range than average when TBW was used for dose
calculation.
DISCUSSION
We evaluated the performance of published guidelines
for initial i.v. busulfan dosing in children and found marked
differences between the guidelines identiﬁed with respect to
the likelihood of achieving AUC values within the target
range. In addition, we found that achievement of the desired
AUC in overweight children may be improved by using IBW
or IBWadj.Figure 1. Box plot of AUCs achieved after simulated i.v. busulfan dosing using 12 dos
edges of each box indicate the 25th and 75th percentiles. The center horizontal line is d
point within 1.5 interquartile ranges. The mean is indicated by a diamond. Values ouThe keen concern that children achieve the desired
busulfan dose intensity (AUC or Css) is evidenced by the
multiple dosing guidelines published. Clinicians have a very
brief period of time in which to achieve the dose intensity
required to optimize the likelihood of engraftment and
minimize the likelihood of life-threatening toxicity. An
appreciation of the relative performance of dosing guidelines
is of utmost concern in centers that do not have access to
therapeutic drug monitoring and who must assume that the
suggested doses achieve the desired dose intensity [23]. The
move toward once-daily i.v. busulfan administration also
increases the need to achieve the desired dose intensity withing guidelines in 97 children with TBW/IBW < 1.25. Note: the bottom and top
rawn at the median. Vertical lines are drawn from the box to the most extreme
tside this range are marked with an open circle.
Table 5
AUC Values Achieved and Their Distribution with Respect to the Target Range after Dosing Simulation with 12 i.v. Busulfan Dosing Guidelines in 22 Patients < 1
Year of Age and with TBW/IBW Ratio < 1.25 When Dosed Using TBW
Dosing Guideline (Author, Year of Publication) Simulated AUC Values Distribution of Simulated AUC Values (%
of Patients)
Mean AUC (SD)
mM$min
95% Conﬁdence
Interval
CV (%) 900-1500
mM$min
<900
mM$min
>1500
mM$min
Dosing guidelines that allow ﬂexible AUC targets
Long-Boyle*, 2015 d d d d d d
McCune, 2014; First Dose 1410 (409) 1334-1487 29.0 64 5 32
Paci, 2012 1477 (365) 1324-1629 24.7 50 5 45
Savic, 2013 1472 (406) 1302-1641 27.6 59 5 36
Trame, allometric BW method, 2011 1370 (358) 1224-1517 25.6 59 5 36
Trame, BSA method, 2011 1356 (358) 1207-1506 26.4 55 9 36
Dosing guidelines that do not allow ﬂexible AUC targets
Ansari, 2014 1014 (245) 912-1116 24.1 64 36 0
Bartelink, 2012 1531 (364) 1379-1684 23.8 45 0 55
Booth, 2007 1394 (336) 1254-1535 24.1 59 5 36
Bufferyy, 2014 d d d d d d
Nguyen, 2004 1298 (300) 1172-1423 23.1 64 14 23
Wall, 2010 1268 (306) 1140-1395 24.1 64 14 23
* Excluded from analysis because no patients < 1 year of age were >12 kg.
y Excluded from analysis because only 2 patients were <1 year of age and 10 kg.
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is administered before the dose can be individualized based
on therapeutic drug monitoring. Although administration of
a test dose may address some of these concerns, this may be
logistically challenging. Even in centers where patients’
busulfan doses are routinely adjusted based on therapeutic
drug monitoring, a dosing guideline that is more likely to
achieve the desired dose intensity immediately will lead to
more patients receiving optimal busulfan doses for a higher
proportion of their conditioning. Ideally, an initial busulfan
dosing guideline would be simple, practical, and easy to use
at a patient’s bedside; have few limitations; be inclusive of a
wide variety of ages and weights; and reliably achieve the
desired AUC after both every-6-hour and every-24-hour
dosing.
Determining the initial busulfan dose is challenging
because multiple patient characteristics, including TBW, age,
and BSA, inﬂuence busulfan pharmacokinetic disposition
[1-3,5]. As a result, there is a large interpatient variability in
busulfan clearance. Lee et al. [24] observed clearance ratesTable 6
AUC Values Achieved after Dosing Simulation with 12 i.v. Busulfan Dosing Guideli
Weight Descriptors
Dosing Guideline (First
Author, Year of Publication)
TBW IBW
Mean AUC
(SD) mM$min
95% Conﬁdence
Interval
CV (%) Mean AU
mM$min
Dosing guidelines that allow ﬂexible AUC targets
Long-Boyle, 2015 1775 (315) 1610-1940 17.7 1289 (22
McCune, 2014; ﬁrst dose 1468 (243.7) 1341-1596 16.6 NA
Paci, 2012 1382 (238.8) 1257-1507 17.3 1001 (18
Savic*, 2013 d d d d
Trame, allometric BW
method, 2011
1115 (192.7) 1015-1216 17.3 812 (14
Trame, BSA method, 2011 981 (171.7) 891-1071 17.5 795 (15
Dosing guidelines that do not allow ﬂexible AUC targets
Ansari, 2014 1429 (285.8) 1280-1579 20.0 931 (17
Bartelinky, 2012 1439 (282.8) 1285-1592 19.7 1139 (22
Booth, 2007 1409 (297.5) 1254-1565 21.1 915 (16
Buffery, 2014 1450 (280.0) 1303-1597 19.3 978 (21
Nguyen, 2004 1455 (278.5) 1309-1601 19.1 978 (19
Wall, 2010 1429 (285.8) 1280-1579 20.0 931 (17
* Excluded because no overweight patient had a TBW < 12 kg.
y One patient excluded in the TBW simulation due to TBW > 20% the uppermosfrom 1.74 to 6.94 mL/min/kg after administration of a once-
daily dose of 120 mg/m2 in 23 children aged .9 to 18.1
years (median, 9.3 years). This was echoed by Nath et al. [25],
who observed a coefﬁcient of variation of 35% in the clear-
ance of busulfan in 40 children. Although some of this vari-
ability may be partially explained by pharmacokinetic
polymorphisms, the data supporting this have been incon-
sistent [26-28].
Six of the identiﬁed busulfan dosing guidelines were less
likely to achieve a simulated AUC within the target range
using TBW in non-overweight patients. Interestingly, the
guideline that forms the basis for the EMA-approved dosing
for i.v. busulfan [18] was included in this group.
Emerging evidence suggests that the therapeutic AUC
range of 900 to 1500 mM$min should not be universally
applied. That is, the optimal AUC may depend on the indi-
cation for transplant or other patient-related factors. For
example, patients undergoing HSCT for the treatment of
thalassemia or sickle cell anemia may achieve excellent
outcomes with busulfan AUC targets at the low end of thenes in 14 Patients with TBW/IBW Ratio  1.25 When Dosed Using Different
IBWadj
C (SD) 95% Conﬁdence
Interval
CV (%) Mean AUC
(SD) mM$min
95% Conﬁdence
Interval
CV (%)
3.2) 1172-1406 17.3 1421 (239.0) 1296-1546 16.8
NA NA NA NA NA
1.3) 906-1096 18.1 1118 (191.7) 1017-1218 17.2
d d d d d
8.3) 734-890 18.3 905 (156.0) 823-987 17.3
1.2) 716-874 19.0 854 (153.4) 774-934 18.0
1.2) 841-1021 18.4 1079 (200.8) 974-1184 18.9
6.9) 1020-1258 19.9 1243 (227.7) 1124-1362 18.2
4.8) 829-1002 18.0 1063 (202.3) 957-1169 19.3
4.1) 865-1090 21.9 1121 (219.6) 1006-1236 19.8
0.5) 878-1078 19.5 1118 (196.5) 1015-1221 18.1
1.2) 841-1021 18.4 1079 (200.8) 974-1184 18.9
t body weight category.
Table 7
Distribution of AUC Values Achieved after Dosing Simulationwith 12 i.v. Busulfan Dosing Guidelines Using Different BodyWeight Descriptors in 14 Patients with
TBW/IBW Ratio  1.25
Dosing Guideline (First Author,
Year of Publication)
Distribution of Simulated AUC Values (% of Patients)
TBW IBW IBWadj
900-1500
mM$min
<900
mM$min
>1500
mM$min
900-1500
mM$min
<900
mM$min
>1500
mM$min
900-1500
mM$min
<900
mM$min
>1500
mM$min
Dosing guidelines that allow ﬂexible AUC targets
Long-Boyle, 2015 21 0 79 86 0 14 64 0 36
McCune, 2014; ﬁrst dose 43 7 50 d d d d d d
Paci, 2012 64 0 36 64 36 0 71 21 7
Savic*, 2013 d d d d d d d d d
Trame, allometric BW
method, 2011
79 21 0 36 64 0 50 50 0
Trame, BSA method, 2011 64 36 0 29 71 0 43 57 0
Dosing guidelines that do not allow ﬂexible AUC targets
Ansari, 2014 50 7 43 57 43 0 79 21 0
Bartelinky, 2012 46 0 54 79 14 7 86 0 14
Booth, 2007 50 7 43 50 50 0 79 21 0
Buffery, 2014 43 7 50 64 36 0 79 21 0
Nguyen, 2004 43 7 50 64 36 0 79 21 0
Wall, 2010 50 7 43 57 43 0 79 21 0
* Excluded because no overweight patient had a TBW < 12 kg.
y One patient excluded in the TBW simulation due to TBW > 20% the uppermost body weight category.
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proposed that AUC targets at the lower end of the traditional
target range lead to optimal HSCT outcomes in children
regardless of the indication for HSCT [31]. For example,
Bartelink et al. [2] suggest that targeting an AUC of 1125 to
1250 mM$min after every 6 hourly dosing will optimize HSCT
outcomes in children. To accommodate individualization of
target dose intensity, we recommend that clinicians use 1 of
3 guidelines for initial i.v. busulfan dosing that have a higher
likelihood of achieving the target range and that incorporate
the target AUC or Css into the dosing algorithm [7,14,19,21]
for children who are not overweight (TBW/IBW < 1.25).
The recommended guidelines were developed using
different pharmacokinetic models (1 compartment [14], 2
compartment [19], and Michaelis-Menten [7]) and pop-
ulations of different ages (<15 years [14],<66 years [19], and
<24 years [7]). In addition, the recommended guidelines
apply different patient parameters (body weight [14]; sex,
gestational age, postnatal age, body weight, and height [19];
and body weight and age [7]) to the calculation of the initial
busulfan dose. However, given the similarity in the propor-
tion of patients who achieved a target AUC, it is not obvious
that variables other than body weight contribute to the
guidelines’ ability to achieve the target AUC values. Use of a
novel patient parameter such as pharmacogenetic poly-
morphism may be required to improve the performance of
future pediatric i.v. busulfan dosing guidelines.
Infants and overweight patients may require a different
approach to i.v. busulfan dosing. Infants may have busulfan
pharmacokinetic disposition distinct from older children
that result in different dose requirements [4,32]. However,
none of the guidelines was superior in the ability to achieve
an AUC value within the target range for infants.
Browning et al. [33] determined that children with a high
body mass index required a lower busulfan dose (2.9 mg/kg/
day using TBW) to achieve the same AUC as children with
normal (4.0 mg/kg/day) or low body mass indices (3.6 mg/
kg/day). However, body mass index does not describe body
composition (lean versus fat) and is therefore not recom-
mended for drug dosing [34]. We also observed a high pro-
portion of simulated AUC values above the target range inoverweight patients when TBW was used to calculate initial
i.v. busulfan doses, with 1 exception. The dosing guideline of
Trame et al. [17] led to no simulated AUC values above the
target range. The highest proportion of simulated AUC values
within the target rangewas achieved by the dosing guideline
developed by Long-Boyle et al. [7] and the use of IBW and
that of Bartelink et al. [6] and the use of IBWadj. However, the
supplementary dose calculation tool that accompanies the
Long-Boyle guideline cannot be used in children older than
17 years. Use of IBWadj and the Bartelink et al. dosing
guideline [6] may therefore be preferred in overweight pa-
tients, although it must be appreciated that this guideline
may not be valid for children who weigh more than 87.4 kg.
Use of IBWadj and the Paci et al. dosing guideline [14] may be
a reasonable alternative.
Our study is restricted by its retrospective nature. It
describes the performance of the dosing regimens with
respect to simulated AUC values based on retrospective
patient data. The trends observed regarding the mean AUC
values achieved using each guideline and the variability
around these values are likely to hold true in different
patient cohorts. Nevertheless, the performance of the rec-
ommended i.v. busulfan dosing guidelines requires pro-
spective evaluation.
In summary, we evaluated the performance of 12 pub-
lished i.v. busulfan pediatric dosing guidelines using a
retrospectively collected patient database. When selecting
which dosing guideline to use, clinicians should balance the
potential consequences of under- or overshooting the
intended target dose intensity and the tendency of each
guideline to predict doses that will achieve AUCs in the
central, upper, or lower bounds of the target range. For
children who are not overweight, including infants, we
speciﬁcally recommend 1 of 3 high-performing guidelines
that allow individualization of the target busulfan dose
intensity. For children who are overweight, use of IBW or
IBWadj may optimize achievement of an AUC within the
target range. However, because the coefﬁcient of variation
of the simulated AUC values achieved by every guideline
was high, veriﬁcation and individualization of the appro-
priate dose using therapeutic drug monitoring after
J.H. Zao et al. / Biol Blood Marrow Transplant 21 (2015) 1471e14781478administration of the ﬁrst i.v. busulfan dose is highly
recommended regardless of the dosing guideline used.
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